Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report

Abstract

Background: Multiple myeloma (MM) is a clonal plasma cell malignancy often treated with multidrug regimens and autologous stem cell transplantation (ASCT), followed by maintenance therapy with lenalidomide. While lenalidomide has proven efficacy in prolonging remission, it is associated with a rare but significant risk of second primary malignancies, including therapy-related B-cell acute lymphoblastic leukemia (B-ALL).

Case presentation: We report the case of a 73-year-old white American male diagnosed with IgA kappa MM in 2020, treated with six cycles of Bortezomib, Dexamethasone, and Lenalidomide, followed by maintenance lenalidomide therapy. In June 2023, the patient presented with thrombocytopenia during routine follow-up. Bone marrow biopsy confirmed B-ALL, with flow cytometry revealing a neoplastic population consistent with B-lymphoblasts. Lenalidomide was discontinued, and the patient commenced R-hyper-CVAD chemotherapy followed by intrathecal methotrexate. Despite initial plans for allogeneic stem cell transplantation, the procedure was delayed due to persistent COVID-19 positivity. The patient achieved complete remission of B-ALL and opted for surveillance only, prioritizing quality of life.

Conclusion: This case highlights the potential for B-ALL as a secondary malignancy in patients on lenalidomide maintenance therapy, in a relatively short time, without prior ASCT. Early recognition of unexplained cytopenia in such patients is critical, necessitating prompt evaluation with bone marrow biopsy. Further research is needed to elucidate the mechanisms underlying lenalidomide-associated secondary malignancies and optimize patient management strategies.

A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma
Takayuki Nakamura, Fumihiko Mouri, Yoshimi Maehiro +8
Internal Medicine22 Sep 2026Peer-reviewedCC BY-NC-NDFull textEpidemiology & public healthJ-STAGE
SECONDARY B-LYMPHOBLASTIC TRANSFORMATION IN A PATIENT WITH MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS TRANSPLANTATION AND LENALIDOMIDE MAINTENANCE: A CASE REPORT
Beatriz Moura PORTUGAL, Maura Alice Santos ROMEO, Valney Oliveira Santos JUNIOR +3
Hematology, Transfusion and Cell Therapy23 Oct 2026Peer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM).
Matthew Strelau, Gregoire Le Gal, Arleigh McCurdy +8
Current oncology (Toronto, Ont.)20 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Thierry Facon, Shaji K. Kumar, Robert Z. Orlowski +29
Leukemia24 Aug 2026Peer-reviewedCC BY 4.0Full textGeneral medicinePMC
Purpureocillium lilacinum Fungemia Masquerading as an Unidentified Yeast in a Heavily Immunosuppressed Patient With Relapsed Multiple Myeloma and Therapy-Related Mixed-Phenotype Acute Leukemia: A Case Report
Mostafa M Abouzahra, Enas Abdallah, Carolyn K Lackore +2
Cureus19 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{zahid2026lenalidomideassociated,
  title = {{Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report}},
  author = {Ibrahim Zahid and Ali Abbas Mankani and Matthew Kelly},
  journal = {Journal of Medical Case Reports},
  year = {2026},
  month = aug,
  doi = {10.1186/s13256-026-06453-6},
  url = {https://doi.org/10.1186/s13256-026-06453-6},
  note = {CC BY-NC-ND 4.0},
}

RIS

TY  - JOUR
TI  - Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report
AU  - Ibrahim Zahid
AU  - Ali Abbas Mankani
AU  - Matthew Kelly
PY  - 2026
DA  - 2026/08/09
JO  - Journal of Medical Case Reports
DO  - 10.1186/s13256-026-06453-6
UR  - https://doi.org/10.1186/s13256-026-06453-6
AB  - Background: Multiple myeloma (MM) is a clonal plasma cell malignancy often treated with multidrug regimens and autologous stem cell transplantation (ASCT), followed by maintenance therapy with lenalidomide. While lenalidomide has proven efficacy in prolonging remission, it is associated with a rare but significant risk of second primary malignancies, including therapy-related B-cell acute lymphoblastic leukemia (B-ALL).  Case presentation: We report the case of a 73-year-old white American male diagnosed with IgA kappa MM in 2020, treated with six cycles of Bortezomib, Dexamethasone, and Lenalidomide, followed by maintenance lenalidomide therapy. In June 2023, the patient presented with thrombocytopenia during routine follow-up. Bone marrow biopsy confirmed B-ALL, with flow cytometry revealing a neoplastic population consistent with B-lymphoblasts. Lenalidomide was discontinued, and the patient commenced R-hyper-CVAD chemotherapy followed by intrathecal methotrexate. Despite initial plans for allogeneic stem cell transplantation, the procedure was delayed due to persistent COVID-19 positivity. The patient achieved complete remission of B-ALL and opted for surveillance only, prioritizing quality of life.  Conclusion: This case highlights the potential for B-ALL as a secondary malignancy in patients on lenalidomide maintenance therapy, in a relatively short time, without prior ASCT. Early recognition of unexplained cytopenia in such patients is critical, necessitating prompt evaluation with bone marrow biopsy. Further research is needed to elucidate the mechanisms underlying lenalidomide-associated secondary malignancies and optimize patient management strategies.
SN  - 1752-1947
ER  -

Abstract

Related

Cite